-
Publication Venue For
-
Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia.
42:425-433.
2016
-
3-HYDROXYKYNURENINE AND COGNITIVE IMPAIRMENT IN FIRST-EPISODE NEUROLEPTIC-NAIVE PATIENTS WITH SCHIZOPHRENIA.
35:151-151.
2009
-
Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia..
35:336-346.
2009
-
EFFICACY AND TOLERABILITY OF ADJUNCTIVE ARMODAFINIL IN PATIENTS WITH SCHIZOPHRENIA.
35:356-357.
2009
-
NEUROSTEROIDS AS NOVEL THERAPEUTIC AGENTS IN SCHIZOPHRENIA AND PTSD.
35:368-368.
2009
-
Voxel-based morphometric multisite collaborative study on schizophrenia..
35:82-95.
2009
-
fMRI activity correlated with auditory hallucinations during performance of a working memory task: data from the FBIRN consortium study..
35:47-57.
2009
-
Implementation considerations for multisite clinical trials with cognitive neuroscience tasks..
34:656-663.
2008
-
How should DSM-V criteria for schizophrenia include cognitive impairment?.
33:912-920.
2007
-
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia..
31:5-19.
2005
-
Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment..
30:3-20.
2004
-
Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia..
30:587-598.
2004
-
Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: demographic, clinical, and health correlates..
30:45-57.
2004
-
Revised PORT recommendations..
30:609-611.
2004
-
The Texas medication algorithm project: clinical results for schizophrenia..
30:627-647.
2004
-
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients..
30:577-586.
2004
-
Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial..
29:33-43.
2003
-
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale..
29:45-55.
2003
-
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development..
29:15-31.
2003
-
Concealed medicines for people with schizophrenia: a U.S. perspective..
28:537-542.
2002
-
Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia..
27:697-708.
2001
-
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis..
25:201-222.
1999
-
Common sense, insight, and neuropsychological test performance in schizophrenia patients..
22:635-641.
1996
-
DEFICIENT VISUAL ODDBALL STIMULUS PROCESSING PREDICTS PSYCHOSIS ONSET: RESULTS FROM THE NORTH AMERICAN PRODROME LONGITUDINAL STUDY
2020
-
26.2 FORMATIVE RESEARCH TO INFORM A CULTURALLY TAILORED FAMILY PSYCHOEDUCATION INTERVENTION FOR ADULTS WITH PSYCHOTIC DISORDERS IN TANZANIA
2019
-
16.1 EPIGENETIC SIGNATURES OF CHILDHOOD AND ADOLESCENT VICTIMISATION USING A GENETICALLY SENSITIVE LONGITUDINAL COHORT STUDY.
2018
-
O12.3. PROTECTIVE FACTORS FOR PSYCHOTIC EXPERIENCES AMONGST ADOLESCENTS EXPOSED TO MULTIPLE FORMS OF VICTIMIZATION
2018
-
O8.3. CLINICAL AND FUNCTIONAL OUTCOMES IN YOUNG ADULTHOOD OF CHILDREN WITH PSYCHOTIC SYMPTOMS: A LONGITUDINAL TWIN COHORT STUDY
2018
-
RANDOMIZED CONTROLLED TRIAL OF A NEUROSTEROID INTERVENTION IN SCHIZOPHRENIA
2017
-
EFFECTS OF COGNITIVE REMEDIATION ON NEGATIVE SYMPTOMS DIMENSIONS: EXPLORING THE ROLE OF WORKING MEMORY
2015
-
FINDING THE SITES OF GLUTAMATE CIRCUITRY ABNORMALITY IN SCHIZOPHRENIA WITH PROTON MRS
2015
-
GABA AND GLUTAMATE DYSFUNCTION IN SCHIZOPHRENIA: DISTINGUISHING MEDICATION EFFECTS FROM NEUROBIOLOGY
2015
-
MODELING THE EXPRESSION AND COURSE OF DEVELOPMENTAL ABNORMALITIES PRECEDING ADULT SCHIZOPHRENIA: CHARACTERIZATION OF A NEW DEVELOPMENTAL ULTRA-HIGH-RISK GROUP IN 2 BIRTH COHORTS
2011
-
SLEEP PATTERNS OF INDIVIDUALS WITH SCHIZOPHRENIA
2011
-
FRONTAL CORTEX GABA, OSCILLATIONS, AND WORKING MEMORY IN SCHIZOPHRENIA
2011
-
DEVELOPMENT OF AN INTERVIEW-BASED "CO-PRIMARY'' MEASURE OF COGNITION
2009
-
DIFFERENTIATING VOLITION FROM HEDONIA USING A MONITARY REWARD TASK DURING FMRI
2009
-
EVALUATION OF THE EFFECTS OF AL-108 ON NEUROCOGNITION IN SCHIZOPHRENIA: INITIAL TURNS STUDY RESULTS
2009
-
Clozapine increases the neurosteroid pregnenolone in rat hippocampus, cerebral cortex, and serum: Relevance to superior efficacy?
2007
-
Pregnenolone reductions in parietal cortex are associated with suicide in patients with schizophrenia
2007
-
A brief cognitive assessment tool for schizophrenia (B-CATS): Scale construction
2007
-
Efficiency of the BACS and CATIE neuropsychological batteries in assessing cognition and antipsychotic treatment related change in cognition during the CAFE clinical trial
2007
-
Disrupted task related activation to action selection and conflict resolution in patients with schizophrenia
2005
-
Neuroactive steroid alterations in schizophrenia and bipolar disorder: Negative ion chemical ionization gas chromatography/mass spectrometry investigations in posterior cingulate and parietal cortex
2005
-
Neuropsychological deficits at age 13 and later schizophreniform disorder: A longitudinal birth cohort study
2005
-
Olanzapine and fluoxetine effects on hippocampal pregnenolone and peripheral deoxycorticosterone: Relevance to therapeutic efficacy
2005